| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | $2.8M-96.3% | $73.9M | $0 | $0 |
| Cost of product revenue | $14.7M+208.9% | $4.8M | $0 | $0 |
| Cost of license revenue | $2.5M+383.7% | $516K | — | — |
| Research And Development Expense | $148.1M-34.9% | $227.7M+74.5% | $130.5M+52.4% | $85.6M |
| Selling, general and administrative | $120.6M+4.4% | $115.5M+52.8% | $75.5M+23.3% | $61.3M |
| Total cost and operating expenses | $285.9M-17.9% | $348.4M+69.1% | $206.1M+40.3% | $146.9M |
| Loss from operations | -$127.8M+41.2% | -$217.3M-5.4% | -$206.1M-40.3% | -$146.9M |
| Gain from sale of priority review voucher | $0-100.0% | $108.0M | $0 | $0 |
| Investment Income, Net | $18.5M-6.2% | $19.7M+14.6% | $17.2M+262.1% | $4.7M |
| Other (expense) income, net | -$19K-101.6% | $1.2M+3142.5% | -$40K-122.2% | -$18K |
| Total non-operating income, net | $18.5M-85.7% | $128.9M+651.8% | $17.1M+262.7% | $4.7M |
| Loss before income taxes | -$109.3M-23.7% | -$88.4M+53.2% | -$188.9M-32.9% | -$142.2M |
| Income tax benefit (expense) | $2.0M+127.7% | -$7.1M | $0 | $0 |
| Net loss | -$107.3M-12.4% | -$95.5M+49.5% | -$188.9M-32.9% | -$142.2M |
| Net loss per share, basic | -$1040.00-2.0% | -$1020.00+57.0% | -$2370.00-9.2% | -$2170.00 |
| Net loss per share, diluted | -$1040.00-2.0% | -$1020.00+57.0% | -$2370.00-9.2% | -$2170.00 |
| Weighted-average number of common shares used in computing net loss per share, basic | $103205703000.00+10.7% | $93234195000.00+16.9% | $79773004000.00+21.9% | $65466773000.00 |
| Weighted-average number of common shares used in computing net loss per share, diluted | $103205703000.00+10.7% | $93234195000.00+16.9% | $79773004000.00+21.9% | $65466773000.00 |
| Product revenue, net [Member] | ||||
| License revenue [Member] | ||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.